Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.33 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.33 |
| ▸ | NTSR1 | P30989 | 8/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12788909 | 0.93 | DHFR (0.36) | DHFRIDO1TDO2IDO2IP6K1 | |
| SCHEMBL12788945 | 0.89 | DHFR (0.35) | DHFRIDO1TDO2IDO2IP6K1 | |
| SCHEMBL12788906 | 0.86 | NTSR1 (0.40) | DHFRIP6K1NTSR1ALDH1A1MAPK1 | |
| SCHEMBL12789818 | 0.85 | DHFR (0.32) | DHFR | |
| SCHEMBL12788508 | 0.85 | DHFR (0.41) | DHFRIP6K1ALDH1A1MAPK1RAB9A | |
| SCHEMBL12846932 | 0.84 | DHFR (0.39) | DHFRIDO1TDO2IDO2IP6K1 | |
| SCHEMBL12788544 | 0.84 | DHFR (0.41) | DHFRIP6K1 | |
| SCHEMBL12789648 | 0.83 | DHFR (0.35) | DHFRIDO1TDO2IDO2IP6K1 | |
| SCHEMBL13564458 | 0.83 | DHFR (0.39) | DHFRIDO1TDO2IDO2IP6K1 | |
| SCHEMBL12788953 | 0.83 | NAMPT (0.38) | DHFRIDO1TDO2IDO2IP6K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | MERCK SHARP & DOHME CORP. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | GPR119, GPR39, GPR65 | DHFR 3231/4885IDO1 1580/4885TDO2 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.